Scholar Rock Posts First-Ever Product Revenue in Q3 2026

Scholar Rock crossed a milestone in the third quarter of 2026 that no earlier quarter could claim: it booked its first product revenue. The $570,000 came entirely from initial stocking shipments of ISEMBYLD to the specialty distribution network, set in motion within a week of the FDA's September 11 approval of the drug for spinal muscular atrophy. That figure was small by any commercial standard, and it came in well above the consensus estimate, reflecting how quickly the launch got off the ground.

On the bottom line, the company reported a GAAP loss of $0.81 per share, beating expectations. The result includes $17.9 million in stock-based compensation, a standard non-cash charge for a clinical-stage company that has recently entered commercial operations. The pattern of modest beats on the loss line has been fairly consistent: Scholar Rock has now beaten or matched EPS estimates in five of the last six quarters reported.

More than one-third of the top 140 U.S. SMA treatment centers have already enrolled patients, and nearly all patients are opting into the company's Scholar Rock Supports hub. Those are strong early adoption signals, and management was clear that the path from prescription to infusion can stretch beyond 60 to 90 days early in a launch, with payer access still being established. A drug-specific J-code, which will simplify reimbursement significantly, is not expected until April 1, 2027.

The near-term financial picture is also being shaped by moves outside the income statement. Scholar Rock has agreed to sell a Priority Review Voucher for $205 million, pending regulatory clearance, and has $150 million in undrawn debt capacity available. Those two levers provide meaningful runway as the company funds its U.S. commercial build-out while simultaneously advancing regulatory applications in Europe, where a CHMP opinion on the resubmitted MAA is expected in the first half of 2027, and in Japan, where a launch is anticipated near year-end 2027.

Investors will also be watching the pipeline beyond ISEMBYLD. The Phase 1 study of SRK-439 in healthy volunteers is expected to yield topline data by year-end 2026, with results to be shared in early 2027. The Phase 2 FORGE trial in facioscapulohumeral muscular dystrophy is dosing roughly 60 patients, and the OPAL trial in SMA patients under two years of age continues to enroll. The combination of a freshly commercial lead asset and an active pipeline is what CEO David Hallal described as the foundation to redefine the treatment of neuromuscular disease globally.